Rigontec is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The Company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The Company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens.

TypeSubsidiary
Parent CompanyMerck
HQPlanegg, DE
Founded2014
Websiterigontec.de
Rigontec was founded in 2014 and is headquartered in Planegg, DE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Rigontec Office Locations

Rigontec has offices in Planegg and Cambridge
Planegg, (HQ)
Innovations- und Gründerzentrum Biotechnologie (IZB) 19 Am Klopferspitz
Cambridge,
1 Broadway
Show all (2)
Report incorrect company information

Rigontec Financials and Metrics

Summary Metrics

In total, Rigontec had raised $34.5 m. Rigontec is a subsidiary of Merck
Report incorrect company information

Rigontec Company Life and Culture

Report incorrect company information

Rigontec Frequently Asked Questions

  • When was Rigontec founded?

    Rigontec was founded in 2014.

  • Who are Rigontec competitors?

    Competitors of Rigontec include Novian Health, Respicardia and Acelity.

  • Where is Rigontec headquarters?

    Rigontec headquarters is located at Innovations- und Gründerzentrum Biotechnologie (IZB) 19 Am Klopferspitz, Planegg.

  • Where are Rigontec offices?

    Rigontec has offices in Planegg and Cambridge.

  • How many offices does Rigontec have?

    Rigontec has 2 offices.